New Delhi: The determination to include Bharat Biotech’s COVID-19 vaccine Covaxin in World Health Organization’s (WHO) emergency use list (EUL) may badopt within four to six weeks, the global health body’s chief scientist Soumya Swaminathan reported to PTI.
Swaminathan said that WHO is analyzing Covaxin as the creators Bharat Biotech are uploading its entire details on the official portal. As per WHO regulations, EUL is a process to recast the process by which new or unlicensed products can be used during public health emergencies.
“There is a system to be followed for EUL and pre-qualification of antibody under which a company has to finish phase 3 trials and deliver the whole fact to the regulatory department of WHO which is tested by an expert advisory group,” Swaminathan stated at a webinar orchestrated by the Centre for Science and Environment (CSE) on Friday, PTI reported.
Now, six antibodies have been sanctioned by EUL and have recommendations from Strategic Advisory Group of Experts (SAGE). “We pursue to look at Covaxin. Bharat Biotech has now developed an upload of their testimony on our portal and that is the next vaccine that will be scrutinised by our experts committee,” the chief scientist said.
Presently, there are 105 candidate vaccines in clinical assessment out of which 27 are in phase three or four, she stated. There are another 184 candidate antibodies in diagnosis. Most of the antibodies are planned for a two-dose program, she added.
On the Delta variant of the coronavirus, The WHO chief scientist stated it is very contractible. “Two complete doses are necessary for protection against the Delta variant but you can still get the disease and can contract it. This is why masking and other precautions are vital to continue,” she said.